Minimal residual disease monitoring in PTLD
- Conditions
- Circulating tumor DNA Post-transplant lymphoproliferative disorder18F-flurodeoxyglucose positron emission tomography/computed tomography Minimal residual disease
- Registration Number
- NL-OMON22796
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Patients having undergone a SOT or HSCT
-Histologically proven CD20+ monomorphic PTLD (with or without EBV association),
Exclusion Criteria
-A complete surgical resection of tumor.
-Upfront treatment with external beam radiation therapy.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method